Amylyx is dedicated to developing innovative, disease-modifying therapies for neurodegenerative diseases. We have demonstrated robust preclinical data in a variety of in vitro and in vivo models of disease, and multiple studies are ongoing to evaluate our lead candidate, AMX0035, in other neurological indications. We intend to translate AMX0035 to a clinical study in patients suffering from ALS early next year